(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2009 (14.05.2009)

PCT

(10) International Publication Number
WO 2009/061003 A3

(51) International Patent Classification:
A61K 9/127 (2006.01) *A61K 48/00* (2006.01)
A61K 47/40 (2006.01) *C12N 15/87* (2006.01)
A61K 47/48 (2006.01)

(21) International Application Number:
PCT/JP2008/070642

(22) International Filing Date:
6 November 2008 (06.11.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2007-291317 8 November 2007 (08.11.2007) JP

(71) Applicant *(for all designated States except US)*: **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 9, Kanda-Tsukasamachi 2-chome, Chiyoda-ku, Tokyo, 1018535 (JP).

(72) Inventor; and
(71) Applicant : **TAKEUCHI, Hirofumi** [JP/JP]; c/o GIFU PHARMACEUTICAL UNIVERSITY, 5-6-1, Mitahorahigashi, Gifu-shi, Gifu, 5028585 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **TOZUKA, Yuichi** [JP/JP]; c/o GIFU PHARMACEUTICAL UNIVERSITY, 5-6-1, Mitahorahigashi, Gifu-shi, Gifu, 5028585 (JP). **HIRA, Yasuyuki** [JP/JP]; c/o GIFU PHARMACEUTICAL UNIVERSITY, 5-6-1, Mitahorahigashi, Gifu-shi, Gifu, 5028585 (JP). **TOYOBUKU, Hidekazu** [JP/JP]; c/o OTSUKA PHARMACEUTICAL CO., LTD., 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(74) Agents: **Saegusa & Partners** et al.; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
27 May 2010

(54) Title: NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERY COMPOSITION

(57) Abstract: The present invention provides a nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid, such as siRNA or the like, in a cell; and a nucleic acid delivery composition that can efficiently deliver the nucleic acid complex into a cell. A nucleic acid complex with low toxicity and high safety that can persistently maintain a nucleic acid in a cell can be obtained by forming a complex using a nucleic acid to be introduced into a cell, and a highly branched cyclic dextrin. Moreover, when a carrier comprising (A) a diacylphosphatidylcholine, (B) cholesterol and/or a derivative thereof, and (C) an aliphatic primary amine is used as a nucleic acid delivery carrier to introduce the nucleic acid complex into a cell, the safety, the efficiency of intracellular delivery, and the persistence of the nucleic acid in the cell can be further improved.

WO 2009/061003 A3